Noxopharm Ltd
Noxopharm Limited is a clinical-stage biotech company.
The business
Noxopharm Limited is a clinical-stage biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.
Small Caps Research
No research on Noxopharm Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise NOX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Preclinical Data Shows Noxopharm’s Sofra Technology Can Enhance Current Cancer Treatments
Noxopharm's Sofra preclinical data show immune activation with dying cancer cells, hinting Sofra can boost standard cancer therapies.
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Noxopharm data show Sofra's TLR8-boosting oligonucleotides could amplify cancer immunotherapy; US patent backing strengthens breakthrough potential.
Noxopharm SOF-SKN Data Shows Prolonged Skin Retention with Minimal Systemic Absorption
Noxopharm's SOF-SKN shows 3.5-day skin retention, minimal systemic absorption in preclinical tests, guiding dosing regimens and regulatory filings.
Noxopharm Advances HERACLES Trial as Sofra Platform Gains US Momentum
Noxopharm (ASX: NOX) has successfully completed the second dosing cohort in its first-in-human HERACLES trial for novel autoimmune drug candidate SOF-SKN. The safety steering committee confirmed the dose level was safe and tolerable, enabling the study to progress to a higher concentration in the next cohort. The company also reported promising preclinical results from a […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.